Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Relay Therapeutics Inc
(NQ:
RLAY
)
6.240
-0.250 (-3.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Relay Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
September 05, 2024
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug...
Via
Talk Markets
Topics
Economy
Exposures
Economy
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
August 27, 2024
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030.
Via
Talk Markets
Expert Ratings For Relay Therapeutics
August 07, 2024
Via
Benzinga
RLAY Stock Earnings: Relay Therapeutics Beats EPS for Q2 2024
August 06, 2024
RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
July 30, 2024
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030.
Via
Talk Markets
These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why
July 24, 2024
This article identifies the
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Expert Ratings For Relay Therapeutics
July 17, 2024
Via
Benzinga
Expert Ratings For Relay Therapeutics
June 07, 2024
Via
Benzinga
Key Takeaways From Relay Therapeutics Analyst Ratings
May 10, 2024
Via
Benzinga
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
July 18, 2024
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under...
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Declined 13% In June
July 01, 2024
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read
Via
Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
June 17, 2024
The global
Via
Talk Markets
Relay Therapeutics: Q4 Earnings Insights
February 22, 2024
Via
Benzinga
Relay Therapeutics's Earnings: A Preview
February 21, 2024
Via
Benzinga
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
June 10, 2024
The global
Via
Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
May 27, 2024
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our...
Via
Talk Markets
5 Of 7 AI Categories Rose, Slightly,Over Past Week
May 11, 2024
The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The 7 AI Categories Declined, On Average, The First Week Of May
May 05, 2024
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Via
Talk Markets
RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
April 23, 2024
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...
Via
Talk Markets
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 10, 2024
Via
Benzinga
AI Surge Ending: Only One Category Was Up This Week
April 06, 2024
Six of the 7 categories we cover dropped this week, compared with 3 in March. The data clearly indicates that the surge in this sector is stalling or perhaps is even over.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
March 15, 2024
Dive into the potential of precision medicine stocks poised to revolutionize healthcare and offer substantial growth opportunities.
Via
InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
March 04, 2024
Grand View Research says the global
Via
Talk Markets
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
February 19, 2024
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The 7 Best Penny Stocks for 200% Returns
February 06, 2024
Penny stocks often possess significant upside and these are no different with 200% returns expected by analysts.
Via
InvestorPlace
Earnings Scheduled For February 22, 2024
February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.